A Fluorescent Self-Reporting Vector with GSH Reduction Responsiveness for Nucleic Acid Delivery
- 25 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 4 (7) , 5717-5726
Abstract
Nonviral gene vectors with stimulus responsiveness and self-reporting properties have broad application prospects in gene therapy. Herein, we developed a nanosized reduction-responsive cationic liposomal vector formed from DNS(Zn), in which a naphthalimide–sulfonamide group was used as the glutathione (GSH)-responsive group to generate a blue fluorescence signal at 458 nm. Macrocyclic polyamine (cyclen) was used as a cationic headgroup to facilitate Zn(II) coordination, which may reduce the cytotoxicity and improve transfection efficiency. The Zn-free and nonresponsive analogues were used for comparison. Fluorescent assays revealed that the GSH response of DNS(Zn) could increase the blue fluorescence signal and improve the DNA release in cells. The title material also showed higher positive ζ-potential than its nonresponsive analogue, resulting in stronger DNA binding ability and better cellular uptake. These advantages made DNS(Zn) a good candidate for nonviral gene delivery, and the transfection efficiency in HeLa cells was distinctly higher than that of its analogue and the commercially available transfection reagent. Besides plasmid DNA, DNS(Zn) could also deliver small interfering RNA (siRNA) with good gene silencing efficiency, extending the application of the liposomes. These results suggest that DNS(Zn) can serve as a highly efficient nucleic acid delivery vector with reduction-responsive fluorescence self-reporting ability in tumor cells.Keywords
Funding Information
- Basic Research Programs of Sichuan Province (2020YJ0274)
- National Natural Science Foundation of China (21877082, 21977077)
This publication has 38 references indexed in Scilit:
- Autophagy-inhibiting polymer as an effective nonviral cancer gene therapy vector with inherent apoptosis-sensitizing abilityBiomaterials, 2020
- An artificial cell system for biocompatible gene delivery in cancer therapyNanoscale, 2020
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics, 2020
- Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737Asian Pacific Journal of Cancer Prevention, 2020
- Enhancing global access to cancer medicinesCA: A Cancer Journal for Clinicians, 2020
- Therapeutic bacteria to combat cancer; current advances, challenges, and opportunitiesCancer Medicine, 2019
- Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapyCancer Gene Therapy, 2007
- Biodistribution of Radiolabeled Lipid–DNA Complexes and DNA in MiceJournal of Pharmaceutical Sciences, 1998
- Gene therapy - promises, problems and prospectsNature, 1997
- Synthetic gene-transfer vectorsAccounts of Chemical Research, 1993